Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: Triffin who wrote (537)	2/6/1999 9:09:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 1084

eurekalert.org In the future, it may be possible to predict the success of a bone marrow transplantation by evaluating the highly variable proportion of the patient's stem cells that express the CXCR4 receptor. Furthermore, it may even be possible to pre-select the stem cells equipped with the CXCR4 receptor for transplantation purposes, or to pre-treat the stem cells so that they all display the recptor. These measures should significantly increase the numbers of stem cells transplanted into the patient's bone marrow, and therefore the overall success rate of the procedure . Clinical testing of the method is currently under consideration.